CAR T-Cell Therapy for Hematologic Cancers: Michael Bishop, MD


The professor of medicine and director of the Hematopoietic Stem Cell Transplantation Program at University of Chicago Medicine described the impact of CAR T-cell therapy on the hematologic cancer landscape.

This content originally appeared on our sister site, Targeted Oncology.

Physicians are anticipating a first indication of chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma, after the therapy has made significant impacts in patient care in areas it is approved: non-Hodgkin lymphoma and pediatric and young adult acute lymphoblastic leukemia (ALL). Other recent approvals have been made in mantle cell lymphoma.

Targeted Oncology spoke with Michael Bishop, MD, a professor of medicine and director of Hematopoietic Stem Cell Transplantation Program at University of Chicago Medicine, about the different settings where CAR T-cell therapy is used.

Starting with ALL for the pediatric population, CAR T cells have been a game changer, according to Bishop. These young patients have median overall survivals of less than 6 months, but the high response rates with CAR T are enabling them to potentially go on to an allogeneic stem cell transplant and in some cases, be free of disease.

In the non-Hodgkin lymphoma setting, there are now 3 products indicated for advanced B-cell non-Hodgkin lymphoma, which is significant for patients with totally refractory disease. There is this therapeutic option that is potentially curative. Bishop says investigators are seeing patients out to 5 years without any further therapy after receiving CAR T cells.

Related Videos
Shankar Musunuri, PhD, on Gene Modifier Therapy vs Gene Replacement Therapy for IRDs
Pat Furlong, BSN, RN, on the State of Gene Therapy in Muscular Dystrophy
Michael Kelly, PhD, on Continuing Progress With Gene Therapy in Muscular Dystrophy
Thomas McCauley, PhD, on Potential Advantages of Epigenetic Therapy Over Small Molecule, Gene Therapy
Sharon Hesterlee, PhD, on Unprecedented Progress in Muscular Dystrophies
Related Content
© 2023 MJH Life Sciences

All rights reserved.